{"result": {"id": "f2c3c0e7-8b24-4818-b6cf-df88ce0f99cd", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>醛固酮合成酶<|>organization<|>Aldosterone synthase is an enzyme involved in the production of aldosterone, with activity regulated by genetic mutations in various channels)\n##\n(\"entity\"<|>螺内酯<|>organization<|>Spironolactone is a mineralocorticoid receptor antagonist used as first-line treatment for primary aldosteronism)\n##\n(\"entity\"<|>依普利酮<|>organization<|>Eplerenone is a selective mineralocorticoid receptor antagonist used as an alternative treatment for primary aldosteronism)\n##\n(\"entity\"<|>阿米洛利<|>organization<|>Amiloride is a potassium-sparing diuretic used in the treatment of primary aldosteronism)\n##\n(\"entity\"<|>糖皮质激素<|>organization<|>Glucocorticoids are used in low doses for the treatment of Familial Hyperaldosteronism Type I)\n##\n(\"entity\"<|>原发性醛固酮增多症<|>event<|>Primary aldosteronism is a condition characterized by excessive aldosterone production leading to hypertension and hypokalemia)\n##\n(\"entity\"<|>家族性醛固酮增多症<|>event<|>Familial Hyperaldosteronism is a genetic form of primary aldosteronism with different subtypes)\n##\n(\"relationship\"<|>醛固酮合成酶<|>CYP11B<|>CYP11B chimeric gene has aldosterone synthase activity<|>9)\n##\n(\"relationship\"<|>螺内酯<|>MRA<|>Spironolactone is a type of Mineralocorticoid Receptor Antagonist (MRA)<|>9)\n##\n(\"relationship\"<|>依普利酮<|>MRA<|>Eplerenone is a type of Mineralocorticoid Receptor Antagonist (MRA)<|>9)\n##\n(\"relationship\"<|>阿米洛利<|>MRA<|>Amiloride is used as an alternative to MRAs in treatment<|>7)\n##\n(\"relationship\"<|>糖皮质激素<|>家族性醛固酮增多症<|>Glucocorticoids are used to treat Familial Hyperaldosteronism Type I<|>8)\n##\n(\"relationship\"<|>原发性醛固酮增多症<|>PASO<|>PASO consensus evaluates surgical outcomes for primary aldosteronism<|>8)\n##\n(\"relationship\"<|>家族性醛固酮增多症<|>原发性醛固酮增多症<|>Familial Hyperaldosteronism is a genetic subtype of primary aldosteronism<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558812, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 584, "prompt_tokens": 3117, "total_tokens": 3701, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3072}, "prompt_cache_hit_tokens": 3072, "prompt_cache_miss_tokens": 45}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 醛固酮合成酶)之间不等的遗传重  组 ,形成 CYP11B 嵌合基因 ,其表达受促肾上腺皮质  激素(adrenocorticotropic hormone, ACTH) 调控 , 并  且有醛固酮合成酶的活性[715] 。 Ⅱ 型、Ⅲ型和 Ⅳ型分  别由氯离子电压门控通道 2(chloride voltage-gated channel2, CLCN2) 、内向整流型钾离子通道亚家族 J 成员 5(potassium inwardly rectifying channel sub- familyJ, member5, KCNJ5) 和钙离子电压门控通  道 α1H 亚 单 位 (calcium voltage-gated channel sub- unitα1H, CACNA1H) 胚系基因突变所致 ,导致醛固  酮合成酶活性增加[716-718] 。\n　10.5.3   治疗    包括外科手术及内科药物治疗 , 见 表 30。\n　　　年 龄 <35岁 且 单 侧 肾 上 腺 腺 瘤 或 大 结 节 (> 10 mm)者或经 AVS确诊单侧肾上腺醛固酮优势分 泌者采取手术治疗 , 目前多采用腹腔镜下单侧肾上腺 切除术 。术前应充分纠正血钾和控制血压 ,手术当 日 停用降压药和补钾药物 ,术后应及时复查血钾、ARR\n\n\n并监测血压 。 目前依据原发性醛固酮增多症手术结局 研 究  ( primary  aldosteronism   surgical  outcome, PASO)共识[719]来判定患者的手术效果 。研究显示约 37%患者手术后高血压获得治愈 , 94%患者获得生化 治愈 。 因有术后复发的风险[720]  , 手术患者应接受终 身随访 ,定期复查 ARR和肾上腺影像。\n表 30  原发性醛固酮增多症治疗方法\n\n分型\t一线治疗\t二线治疗\n　单侧 肾 上 腺 病 变 (经 AVS确 认) ,或年龄<35岁且单侧肾上 腺腺瘤或大结节(>10 mm) 者 , 有手术意愿\n双侧肾上腺病变 ,或无手术意愿\n\n\n家族性醛固酮增多症\t腹腔镜下单侧肾上腺切 除术\n\n\n螺内酯\n依普利酮 阿米洛利\n　Ⅰ型使用小剂量糖皮质 激素 ,其余使用螺内酯\t螺内酯\n依普利酮 阿米洛利\n注 :AVS为肾上腺静脉取血。\n\n　　无手术适应证、无手术意愿或不能耐受手术治疗 者 ,采取药物治疗 。一线用药为 MRA,首选推荐螺内 酯 。螺内酯起始剂量为 25~ 50 mg/d,使用初期应每 隔2周复查血钾 ,4周复查肾功能。对于有肾功能不全 的患者 ,应慎用螺内酯 ,eGFR<30mL/(min ·1.73m2) 者应 禁 用 。 使 用 MRA 治 疗 的 患 者 , 如 果 PRA> 1 μg/(L ·h) ,则提示患者心血管事件发生率和死亡 率等同于原发性高血�\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>CYP11B<|>organization<|>CYP11B is a chimeric gene formed by genetic recombination, regulated by ACTH, and has aldosterone synthase activity)\n##\n(\"entity\"<|>ACTH<|>organization<|>Adrenocorticotropic hormone (ACTH) regulates the expression of CYP11B chimeric gene)\n##\n(\"entity\"<|>CLCN2<|>organization<|>Chloride voltage-gated channel 2 (CLCN2) is involved in the genetic mutations causing increased aldosterone synthase activity)\n##\n(\"entity\"<|>KCNJ5<|>organization<|>Potassium inwardly rectifying channel subfamily J member 5 (KCNJ5) is involved in the genetic mutations causing increased aldosterone synthase activity)\n##\n(\"entity\"<|>CACNA1H<|>organization<|>Calcium voltage-gated channel subunit α1H (CACNA1H) is involved in the genetic mutations causing increased aldosterone synthase activity)\n##\n(\"entity\"<|>PASO<|>organization<|>Primary Aldosteronism Surgical Outcome (PASO) consensus is used to determine the surgical outcomes for patients with primary aldosteronism)\n##\n(\"entity\"<|>AVS<|>organization<|>Adrenal Vein Sampling (AVS) is a diagnostic method for confirming unilateral adrenal aldosterone hypersecretion)\n##\n(\"entity\"<|>MRA<|>organization<|>Mineralocorticoid Receptor Antagonists (MRA) are used as first-line treatment for primary aldosteronism)\n##\n(\"relationship\"<|>CYP11B<|>ACTH<|>ACTH regulates the expression of CYP11B chimeric gene<|>8)\n##\n(\"relationship\"<|>CLCN2<|>KCNJ5<|>Both CLCN2 and KCNJ5 are involved in genetic mutations causing increased aldosterone synthase activity<|>6)\n##\n(\"relationship\"<|>KCNJ5<|>CACNA1H<|>Both KCNJ5 and CACNA1H are involved in genetic mutations causing increased aldosterone synthase activity<|>6)\n##\n(\"relationship\"<|>PASO<|>AVS<|>PASO consensus is used to evaluate surgical outcomes for patients diagnosed via AVS<|>7)\n##\n(\"relationship\"<|>MRA<|>AVS<|>MRA is used as a treatment for patients who are not candidates for surgery or AVS<|>5)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_5531e45cd7e7907e09cf4f2653332c6cd0ee1160610f60ae26fd3555bdc8a6ee_v2"}